Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 204 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ATP Clear all
Completed Not applicable Interventional

Mind-Body Rehabilitative Program for Veterans With mTBI (Mild Traumatic Brain Injury)

NCT01975857
View directory record Official record
Conditions
Sleep Disturbance, Traumatic Brain Injury
Interventions
Mind-Body Bridging Program, Supportive Education
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 18, 2026, 5:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of Menstrual Phase on Oral Glucose Sensitivity

NCT06800690
View directory record Official record
Conditions
Ovulation, Menstruation
Interventions
Urinary Estrogen Level
Diagnostic Test
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 46 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 4 Interventional Results available

Myositis Interstitial Lung Disease Nintedanib Trial

NCT05799755
View directory record Official record
Conditions
Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions
Nintedanib, Placebo, Standard of Care
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

NCT00720798
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Disease-modifying anti-rheumatic drugs, Non-steroidal anti-inflammatory drugs, Oral corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
138
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 18, 2026, 5:40 AM EDT
Completed No phase listed Observational

Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency

NCT05050669
View directory record Official record
Conditions
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Generalized Arterial Calcification of Infancy, Autosomal Recessive Hypophosphatemic Rickets, Adenosine Triphosphate Binding Cassette Transporter Protein Subfamily C Member 6
Interventions
No Intervention for this observational study
Other
Lead sponsor
Inozyme Pharma
Industry
Eligibility
2 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 2 Interventional

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

NCT00370383
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
70 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
11
States / cities
Anaheim, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 18, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional Results available

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

NCT05263505
View directory record Official record
Conditions
Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
Interventions
Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine, Mycophenolate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 18, 2026, 5:40 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Measurement of Platelet Dense Granule Release in Healthy Volunteers

NCT00942617
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Aspirin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 18, 2026, 5:40 AM EDT
Withdrawn Phase 2 Interventional

Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

NCT01275287
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Standard of care treatment, eculizumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

NCT01141504
View directory record Official record
Conditions
Healthy Subjects
Interventions
PeakATP 250, Placebo, PeakATP 400, PeakATP 400 plus proprietary blend
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
20 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Effectiveness of a Family Heart Health Educational Program (The FIT-Heart Study)

NCT00728637
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases
Interventions
Family Passport to Heart Health Program, General Educational Materials
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 79 Years
Enrollment
501 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 18, 2026, 5:40 AM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

NCT01072175
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436, GSK1120212
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 18, 2026, 5:40 AM EDT
Completed No phase listed Observational

Bladder and Bone Effects of Pelvic Radiation Therapy in Childhood Cancer Survivors

NCT05818462
View directory record Official record
Conditions
Cancer, Childhood Cancer
Interventions
Uroflow testing, Bladder Scan, Dysfunctional Voiding Scoring System Survey, DEXA Scan of pelvis and sacral spine, Urine tests for specific biomarkers
Diagnostic Test · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Tyrosol and Creatine on Exercise Performance and Cognition in Healthy Adults

NCT07756658
View directory record Official record
Conditions
Tyrosol, Creatine, Endurance Performance, Cognition, Mood
Interventions
Tyrosol, Creatine Monohydrate, Resistant Dextrin
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Enrolling by invitation Phase 4 Interventional

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

NCT02081755
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Everolimus, Tacrolimus, Myfortic, CellCept, Imuran
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 18, 2026, 5:40 AM EDT
Completed No phase listed Observational

Interactions of Environmental and Human Microbial Communities in a Pediatric Oncology Hospital

NCT02948335
View directory record Official record
Conditions
Infection
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 18, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional Results available

Etanercept for the Treatment of Lupus Nephritis

NCT00447265
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Etanercept, Lupus Treatment- Standard of Care, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

NCT01860963
View directory record Official record
Conditions
Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions
Anal Pap smear and HPV DNA testing
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Acupuncture for Vasectomy Pre-procedural Anxiety and Pain Control in the Primary Care Setting

NCT03938415
View directory record Official record
Conditions
Acupuncture, Pain, Postoperative, Vasectomy
Interventions
Acupuncture, Standardized pre-procedure medications
Procedure · Other
Lead sponsor
Matthew Snyder
Federal
Eligibility
25 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 18, 2026, 5:40 AM EDT
Completed No phase listed Observational

Natural History Study of Azathioprine Adherence

NCT00143910
View directory record Official record
Conditions
Kidney Transplant
Interventions
observation
Other
Lead sponsor
Thomas E. Nivens, MD
Individual
Eligibility
16 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Incorporating Acupuncture Into ERAS for Ambulatory Total Hip Replacement (THR) Surgery

NCT05384860
View directory record Official record
Conditions
Acupuncture, Hip Surgery, Opioid Use
Interventions
Auricular Trauma Protocol (ATP) Acupuncture, No Acupuncture Group
Device · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 18, 2026, 5:40 AM EDT
Completed Phase 3 Interventional

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

NCT00137462
View directory record Official record
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
48
States / cities
Huntsville, Alabama • Union Grove, Alabama • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2007 · Synced Oct 18, 2026, 5:40 AM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 18, 2026, 5:40 AM EDT